PDF herunterladen
Horm Metab Res
DOI: 10.1055/a-2371-1642
Original Article: Endocrine Care

Efficacy of Recombinant Human Parathyroid Hormone 1–34 and Vitamin K2 Combination Therapy in Postmenopausal Osteoporosis

Zhuo Zhang
1   Surgery of Spine and Bone Tumors, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China
,
Kun Xia
1   Surgery of Spine and Bone Tumors, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China
,
Wentao Gong
1   Surgery of Spine and Bone Tumors, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China
,
Ruopeng Mai
1   Surgery of Spine and Bone Tumors, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China
,
Peng Liu
1   Surgery of Spine and Bone Tumors, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China
,
Zhaogang Lu
2   Department of Clinical Pharmacy, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China
› Institutsangaben Funding Information Hospital training to revitalize research projects | 201905
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1–34 [rhPTH (1–34)] and vitamin K2 therapy versus vitamin K2 alone in the treatment of postmenopausal osteoporosis. A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups. Patients in one group received vitamin K2 alone, while patients in the other group received a combination of rhPTH (1–34) and vitamin K2. Bone mineral density (BMD), electrolyte levels, pain scores, bone metabolism levels, and adverse drug reactions were compared pre- and post-treatment. Both two treatments improved BMD, blood calcium concentrations, pain scores, and increased osteocalcin and osteoprotegerin levels. Notably, the combined rhPTH (1–34) and vitamin K2 treatment demonstrated superior efficacy in improving BMD and bone metabolism markers. Furthermore, there was no significant difference in the incidence of adverse reactions between the two groups, indicating the safety of the combined treatment. In summary, the combined therapy of rhPTH (1–34) and vitamin K2 exhibited more potent efficacy in the treatment of postmenopausal osteoporosis, more effectively enhancing BMD and bone metabolism markers than vitamin K2 alone, without a significant increase in adverse reactions.

Keywords

postmenopausal osteoporosis - recombinant human parathyroid hormone 1-34 - vitamin K2 - BMD - bone metabolism

Supplementary Material



Publikationsverlauf

Eingereicht: 10. April 2024

Angenommen nach Revision: 20. Juli 2024

Artikel online veröffentlicht:
28. August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Yan G, Huang Y, Cao H. et al. Association of breastfeeding and postmenopausal osteoporosis in Chinese women: a community-based retrospective study. BMC Womens Health 2019; 19: 110
    CrossrefPubMedGoogle Scholar
  • 2 Choi MH, Yang JH, Seo JS. et al. Prevalence and diagnosis experience of osteoporosis in postmenopausal women over 50: focusing on socioeconomic factors. PLoS One 2021; 16: e0248020
    CrossrefPubMedGoogle Scholar
  • 3 Zhang X, Wang Z, Zhang D. et al. The prevalence and treatment rate trends of osteoporosis in postmenopausal women. PLoS One 2023; 18: e0290289
    CrossrefPubMedGoogle Scholar
  • 4 Fischer V, Haffner-Luntzer M. Interaction between bone and immune cells: Implications for postmenopausal osteoporosis. Semin Cell Dev Biol 2022; 123: 14-21
    CrossrefPubMedGoogle Scholar
  • 5 Sharma A, Sharma L, Saini RV. et al. Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers. J Pharm Pharmacol 2021; 73: 901-915
    CrossrefPubMedGoogle Scholar
  • 6 Chlebek C, Moore JA, Ross FP. et al. Molecular identification of spatially distinct anabolic responses to mechanical loading in murine cortical bone. J Bone Miner Res 2022; 37: 2277-2287
    CrossrefPubMedGoogle Scholar
  • 7 Li W, Zhang S, Liu J. et al. Vitamin K2 stimulates MC3T3‑E1 osteoblast differentiation and mineralization through autophagy induction. Mol Med Rep 2019; 19: 3676-3684
    PubMedGoogle Scholar
  • 8 Ma ML, Ma ZJ, He YL. et al. Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Front Public Health 2022; 10: 979649
    CrossrefPubMedGoogle Scholar
  • 9 Zhang Y, Liu Z, Duan L. et al. Effect of low-dose vitamin K2 supplementation on bone mineral density in middle-aged and elderly Chinese: a randomized controlled study. Calcif Tissue Int 2020; 106: 476-485
    CrossrefPubMedGoogle Scholar
  • 10 Emaus N, Gjesdal CG, Almås B. et al. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporos Int 2010; 21: 1731-1740
    CrossrefPubMedGoogle Scholar
  • 11 Rønn SH, Harsløf T, Oei L. et al. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. Osteoporos Int 2021; 32: 185-191
    CrossrefPubMedGoogle Scholar
  • 12 Moore AE, Dulnoan D, Voong K. et al. The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial. Arch Osteoporos 2023; 18: 83
    CrossrefPubMedGoogle Scholar
  • 13 Gou P, Zhao Z, Yu C. et al. Efficacy of recombinant human parathyroid hormone versus vertebral augmentation procedure on patients with acute osteoporotic vertebral compression fracture. Orthop Surg 2022; 14: 2510-2518
    CrossrefPubMedGoogle Scholar
  • 14 Leali PT, Balsano M, Maestretti G. et al. Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab 2017; 14: 153-156
    CrossrefPubMedGoogle Scholar
  • 15 Kothari R, Kumar V, Jena R. et al. Modes of degradation and impurity characterization in rhPTH (1-34) during stability studies. PDA J Pharm Sci Rechnol 2011; 65: 348-362
    CrossrefPubMedGoogle Scholar
  • 16 Neer RM, Arnaud CD, Zanchetta JR. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
    CrossrefPubMedGoogle Scholar
  • 17 Deng J, Feng Z, Li Y. et al. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. Medicine (Baltimore) 2018; 97: e13341
    CrossrefPubMedGoogle Scholar
  • 18 Meier C, Lamy O, Krieg M. et al. The role of teriparatide in sequential and combination therapy of osteoporosis. Swiss medical weekly 2014; 144: w13952
    PubMedGoogle Scholar
  • 19 Kanis JA, Melton LJ, Christiansen C. et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141
    CrossrefPubMedGoogle Scholar
  • 20 Kužma M, Vaňuga P, Ságová I. et al. Vertebral fractures occur despite control of acromegaly and are predicted by cortical volumetric bone mineral density. J Clin Endocrinol Metab 2021; 106: e5088-e5096
    PubMedGoogle Scholar
  • 21 Yang JJ, Zhang XM. Clinical efficacy of glucosamine plus sodium hyaluronate for osteoporosis complicated by knee osteoarthritis and its influence on joint function and bone metabolic markers. Comput Math Methods Med 2022; 2022; 6078254
    PubMedGoogle Scholar
  • 22 Li F, Zhu L, Geng Y. et al. Effect of hip replacement surgery on clinical efficacy, VAS score and Harris hip score in patients with femoral head necrosis. Am J Transl Res 2021; 13: 3851-3855
    PubMedGoogle Scholar
  • 23 Kužma M, Jackuliak P, Killinger Z. et al. Parathyroid hormone-related changes of bone structure. Physiol Res 2021; 70: S3-S11
    CrossrefPubMedGoogle Scholar
  • 24 Satterwhite J, Heathman M, Miller PD. et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int 2010; 87: 485-492
    CrossrefPubMedGoogle Scholar
  • 25 Ebeling PR, Russell RG. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. Int J Clin Pract 2003; 57: 710-718
    CrossrefPubMedGoogle Scholar
  • 26 Zhou M, Han S, Zhang W. et al. Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review. J Bone Miner Metab 2022; 40: 763-772
    CrossrefPubMedGoogle Scholar
  • 27 Abdel Aziz DM, Saleh HA, Taha NM. et al. Relation between circulating vitamin k2 level and osteoporosis in post-menopausal women. AQJM Int J Med. 2021 114. hcab116. 002
    PubMedGoogle Scholar
  • 28 Solmaz I, Ozdemir MA, Unal E. et al. Effect of vitamin K2 and vitamin D3 on bone mineral density in children with acute lymphoblastic leukemia: a prospective cohort study. J Pediatr Endocrinol Metab 2021; 34: 441-447
    CrossrefPubMedGoogle Scholar
  • 29 Ying M, Mao J, Sheng L. et al. Biomarkers for prostate cancer bone metastasis detection and prediction. J Pers Med 2023; 13: 705
    CrossrefPubMedGoogle Scholar
  • 30 Subedi L, Pandey P, Kang SH. et al. Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis. J Control Release 2022; 349: 502-519
    CrossrefPubMedGoogle Scholar